The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Helper activity is required for the in vivo generation of cytotoxic T lymphocytes
Open accessAbstract
B6.T1a(a) (Qa-1(a)) mice that are primed in vivo and restimulated in vitro with Qa-1 congenic spleen cells from B6 (Qa-1(b)) animals are unable to generate anti-Qa-1(b) cytotoxic T lymphocytes (CTL). This nonresponsive pattern was observed regardless of the route of immunization or the time of testing in vitro. Although B6.T1a(a) mice are nonresponders to Qa-1(b) when presented on B6 cells, these mice can generate anti-Qa-1(b) CTL when primed in vivo with Qa-1 and H-Y alloantigens (females primed with B6 male cells) or Qa-1 and minor-H- alloantigens (primed with sex-matched A.BY cells). Therefore, the inability to generate anti-Qa-1(b) CTL is due to a lack of helper or accessory antigens on B6 immunizing cells obligatory during in vivo priming, rather than an absence of anti-Qa-1(b) CTL precursors (CTL-P). Demonstration that the additional determinants required during in vivo priming actually function as carrier or helper determinants was shown by the requirement for linked recognition of Qa-1 and the helper determinants (H-Y) in vivo, and the fact that H-Y was not present on susceptible target ceils. Animals primed in vivo with H-Y only could not generate anti-Qa-1 CTL activity when challenged in vitro with both Qa-1 and H-Y, indicating that recognition of the helper determinant causes in vivo priming of CTL-P rather than generating helper activity that might activate unprimed CTL-P in vitro. Whereas unprimed peripheral CTL-P require the presence of both Qa-1 (CTL) and H-Y (helper) determinants for successful in vivo priming, helper determinants were not required in vitro because primed CTL-P from B6.T1a(a) mice could be driven to CTL in vitro using sex-matched B6 stimulator cells. The generation of anti-Qa-1(b) CTL is under immune response (Ir) gene control because F(1) mice, obtained by crossing responder A/J with nonresponder B6.T1a(a) animals, generated CTL to the Qa-1(b) alloantigen when presented on B6 spleen cells. Progeny testing of backcross mice further demonstrated that the Ir gene(s) is linked to the H-2 complex. These data indicate that an H-2-linked Ir gene controls the recognition of helper determinants required for CTL priming in vivo. These helper determinants can be distinguished from CTL determinants and both must be recognized together for successful priming of CTL-P.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The carrier effect in the secondary response to hapten‐protein conjugates. II. Cellular cooperation
Mitchison, N. A. (1971) · European Journal of Immunology · doi:10.1002/eji.1830010104 · Cited by 678
Swain, S. L., Dennert, G., Warner, J. F., & Dutton, R. W. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.4.2517 · Cited by 116
Soluble factors substitute for T–T-cell collaboration in generation of T-killer lymphocytes
PLATE, J. M. D. (1976) · Nature · doi:10.1038/260329a0 · Cited by 99
Okada, M., Klimpel, G. R., Kuppers, R. C., & Henney, C. S. (1979) · PubMed · Cited by 92
Wernet, D., & Lilly, F. (1975) · The Journal of Experimental Medicine · doi:10.1084/jem.141.3.573 · Cited by 34
Bevan, M. J. (1977) · The Journal of Immunology · doi:10.4049/jimmunol.118.4.1370 · Cited by 31
Cited by
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions
Schoenberger, S. P., Toes, R. E. M., van der Voort, E. I. H., Offringa, R., & Melief, C. J. M. (1998) · Nature · doi:10.1038/31002 · Cited by 2,615
A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell
Ridge, J. P., Di Rosa, F., & Matzinger, P. (1998) · Nature · doi:10.1038/30989 · Cited by 2,342
Help for cytotoxic-T-cell responses is mediated by CD40 signalling
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. A. P., & Heath, W. R. (1998) · Nature · doi:10.1038/30996 · Cited by 2,092
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
Janssen, E. M., Lemmens, E. E., Wolfe, T., Christen, U., von Herrath, M. G., & Schoenberger, S. P. (2003) · Nature · doi:10.1038/nature01441 · Cited by 1,635
CD4+ T cell help in cancer immunology and immunotherapy
Borst, J., Ahrends, T., Bąbała, N., Melief, C. J. M., & Kastenmüller, W. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0044-0 · Cited by 1,585
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Fearon, E. R., Pardoll, D. M., Itaya, T., Golumbek, P., Levitsky, H. I., Simons, J. W., Karasuyama, H., Vogelstein, B., & Frost, P. (1990) · Cell · doi:10.1016/0092-8674(90)90591-2 · Cited by 916
Regnault, A., Lankar, D., Lacabanne, V., Rodriguez, A., Théry, C., Rescigno, M., Saito, T., Verbeek, S., Bonnerot, C., Ricciardi-Castagnoli, P., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.2.371 · Cited by 898
Cross-Presentation, Dendritic Cells, Tolerance and Immunity
Heath, W. R., & Carbone, F. R. (2001) · Annual Review of Immunology · doi:10.1146/annurev.immunol.19.1.47 · Cited by 882
Nooraei, S., Bahrulolum, H., Hoseini, Z. S., Katalani, C., Hajizade, A., Easton, A. J., & Ahmadian, G. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-00806-7 · Cited by 869
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
van Stipdonk, M. J. B., Lemmens, E. E., & Schoenberger, S. P. (2001) · Nature Immunology · doi:10.1038/87730 · Cited by 841
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
Helping the CD8+ T-cell response
Bevan, M. J. (2004) · Nature Reviews Immunology · doi:10.1038/nri1413 · Cited by 797
Bennett, S. R. M., Carbone, F. R., Karamalis, F., Miller, J. F. A. P., & Heath, W. R. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.1.65 · Cited by 725
NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway
Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C., Donaldson, D. D., Carbone, D. P., Paul, W. E., & Berzofsky, J. A. (2000) · Nature Immunology · doi:10.1038/82771 · Cited by 699
Ossendorp, F., Mengedé, E., Camps, M., Filius, R., & Melief, C. J. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.5.693 · Cited by 610
Multiple roles for CD4+ T cells in anti‐tumor immune responses
Kennedy, R., & Celis, E. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00616.x · Cited by 511
CD4 T Cells and Their Role in Antitumor Immune Responses
Toes, R. E. M., Ossendorp, F., Offringa, R., & Melief, C. J. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.5.753 · Cited by 508
CD4 cells can be more efficient at tumor rejection than CD8 cells
Perez-Diez, A., Joncker, N. T., Choi, K., Chan, W. F. N., Anderson, C. C., Lantz, O., & Matzinger, P. (2007) · Blood · doi:10.1182/blood-2006-10-051318 · Cited by 437
Sotomayor, E. M., Borrello, I., Tubb, E., Rattis, F.-M., Bien, H., Lu, Z., Fein, S., Schoenberger, S., & Levitsky, H. I. (1999) · Nature Medicine · doi:10.1038/10503 · Cited by 407
Nair, S. K., Boczkowski, D., Morse, M., Cumming, R. I., Lyerly, H. K., & Gilboa, E. (1998) · Nature Biotechnology · doi:10.1038/nbt0498-364 · Cited by 398
COOPERATION BETWEEN CD4+AND CD8+T CELLS: When, Where, and How
Castellino, F., & Germain, R. N. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115825 · Cited by 376
Porgador, A., & Gilboa, E. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.255 · Cited by 362
Scanga, C. A., Mohan, V. P., Yu, K., Joseph, H., Tanaka, K., Chan, J., & Flynn, J. L. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.3.347 · Cited by 350
Vitiello, A., Ishioka, G., Grey, H. M., Rose, R., Farness, P., LaFond, R., Yuan, L., Chisari, F. V., Furze, J., & Bartholomeuz, R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117662 · Cited by 334
Kurts, C., Carbone, F. R., Barnden, M., Blanas, E., Allison, J., Heath, W. R., & Miller, J. F. A. P. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2057 · Cited by 317
Interleukin 2: from immunostimulation to immunoregulation and back again
Bachmann, M. F., & Oxenius, A. (2007) · EMBO reports · doi:10.1038/sj.embor.7401099 · Cited by 303
Immunotherapy of cancer with dendritic-cell-based vaccines
Gilboa, E., Nair, S. K., & Lyerly, H. K. (1998) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050465 · Cited by 287
Shrikant, P., Khoruts, A., & Mescher, M. F. (1999) · Immunity · doi:10.1016/s1074-7613(00)80123-5 · Cited by 283
CD8+ Dendritic Cells Use LFA-1 to Capture MHC-Peptide Complexes from Exosomes In Vivo
Segura, E., Guérin, C., Hogg, N., Amigorena, S., & Théry, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.3.1489 · Cited by 276
Dendritic cells in cancer immunology
Murphy, T. L., & Murphy, K. M. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00741-5 · Cited by 269
Harding, F. A., & Allison, J. P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.177.6.1791 · Cited by 265
Cho, H. J., Takabayashi, K., Cheng, P.-M., Nguyen, M.-D., Corr, M., Tuck, S., & Raz, E. (2000) · Nature Biotechnology · doi:10.1038/75365 · Cited by 258
Effector and memory CD8+ T cells as seen in immunity to malaria
Morrot, A., & Zavala, F. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00175.x · Cited by 55
Metadata
- Authors
- Keene, J.-A., & Forman, J.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 1982-03-01
- Volume
- 155
- Issue
- 3
- Pages
- 768-782
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1980621729
- Cited by
- 500
- References
- 6
- FWCI
- 3.33
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.